Regulation of Nrf2/Keap1 signaling pathway in cancer drug resistance by galectin-1: cellular and molecular implications
- PMID: 38434765
- PMCID: PMC10905161
- DOI: 10.20517/cdr.2023.79
Regulation of Nrf2/Keap1 signaling pathway in cancer drug resistance by galectin-1: cellular and molecular implications
Abstract
Oxidative stress is characterized by the deregulation of the redox state in the cells, which plays a role in the initiation of various types of cancers. The activity of galectin-1 (Gal-1) depends on the cell redox state and the redox state of the microenvironment. Gal-1 expression has been related to many different tumor types, as it plays important roles in several processes involved in cancer progression, such as apoptosis, cell migration, adhesion, and immune response. The erythroid-2-related factor 2 (Nrf2)/Kelch-like ECH-associated protein 1 (Keap1) signaling pathway is a crucial mechanism involved in both cell survival and cell defense against oxidative stress. In this review, we delve into the cellular and molecular roles played by Gal-1 in the context of oxidative stress onset in cancer cells, particularly focusing on its involvement in activating the Nrf2/Keap1 signaling pathway. The emerging evidence concerning the anti-apoptotic effect of Gal-1, together with its ability to sustain the activation of the Nrf2 pathway in counteracting oxidative stress, supports the role of Gal-1 in the promotion of tumor cells proliferation, immuno-suppression, and anti-tumor drug resistance, thus highlighting that the inhibition of Gal-1 emerges as a potential strategy for the restraint and regression of tumor progression. Overall, a deeper understanding of the multi-functionality and disease-specific expression profiling of Gal-1 will be crucial for the design and development of novel Gal-1 inhibitors as anticancer agents. Excitingly, although it is still understudied, the ever-growing knowledge of the sophisticated interplay between Gal-1 and Nrf2/Keap1 will enable researchers to gain valuable insights into the underlying causes of carcinogenesis and metastasis.
Keywords: Galectin-1; Nrf2; cancer drug resistance; oxidative stress.
© The Author(s) 2024.
Conflict of interest statement
All authors declared that there are no conflicts of interest.
Figures


Similar articles
-
Inhibition of the NRF2/KEAP1 Axis: A Promising Therapeutic Strategy to Alter Redox Balance of Cancer Cells.Antioxid Redox Signal. 2021 Jun 20;34(18):1428-1483. doi: 10.1089/ars.2020.8146. Epub 2021 Feb 19. Antioxid Redox Signal. 2021. PMID: 33403898 Review.
-
Hepatocyte-specific NRF2 activation controls fibrogenesis and carcinogenesis in steatohepatitis.J Hepatol. 2021 Mar;74(3):638-648. doi: 10.1016/j.jhep.2020.09.037. Epub 2020 Oct 24. J Hepatol. 2021. PMID: 33342543
-
Ameliorative inhibition of sirtuin 6 by imidazole derivative triggers oxidative stress-mediated apoptosis associated with Nrf2/Keap1 signaling in non-small cell lung cancer cell lines.Front Pharmacol. 2024 Jan 3;14:1335305. doi: 10.3389/fphar.2023.1335305. eCollection 2023. Front Pharmacol. 2024. PMID: 38235110 Free PMC article.
-
MDA-7/IL-24 inhibits Nrf2-mediated antioxidant response through activation of p38 pathway and inhibition of ERK pathway involved in cancer cell apoptosis.Cancer Gene Ther. 2014 Oct;21(10):416-26. doi: 10.1038/cgt.2014.45. Epub 2014 Sep 19. Cancer Gene Ther. 2014. PMID: 25236495
-
Epigenetic Therapeutics Targeting NRF2/KEAP1 Signaling in Cancer Oxidative Stress.Front Pharmacol. 2022 Jun 9;13:924817. doi: 10.3389/fphar.2022.924817. eCollection 2022. Front Pharmacol. 2022. PMID: 35754474 Free PMC article. Review.
Cited by
-
The sweet and the bitter sides of galectin-1 in immunity: its role in immune cell functions, apoptosis, and immunotherapies for cancer with a focus on T cells.Semin Immunopathol. 2025 Apr 3;47(1):24. doi: 10.1007/s00281-025-01047-8. Semin Immunopathol. 2025. PMID: 40178639 Free PMC article. Review.
-
The Central Role of NRF2 in Cancer Metabolism and Redox Signaling: Novel Insights into Crosstalk with ER Stress and Therapeutic Modulation.Cell Biochem Biophys. 2025 Jul 15. doi: 10.1007/s12013-025-01821-3. Online ahead of print. Cell Biochem Biophys. 2025. PMID: 40665070 Review.
-
Critical dysregulated signaling pathways in drug resistance: highlighting the repositioning of mebendazole for cancer therapy.Front Pharmacol. 2025 Jul 25;16:1631419. doi: 10.3389/fphar.2025.1631419. eCollection 2025. Front Pharmacol. 2025. PMID: 40786044 Free PMC article. Review.
-
The multifaceted perspectives on the regulation of lncRNAs in hepatocellular carcinoma ferroptosis: from bench-to-bedside.Clin Exp Med. 2024 Jul 3;24(1):146. doi: 10.1007/s10238-024-01418-9. Clin Exp Med. 2024. PMID: 38960924 Free PMC article. Review.
-
CB5712809, a novel Keap1 inhibitor upregulates SQSTM1/p62 mediated Nrf2 activation to induce cell death in colon cancer cells.Discov Oncol. 2025 Jun 1;16(1):981. doi: 10.1007/s12672-025-02787-7. Discov Oncol. 2025. PMID: 40451905 Free PMC article.
References
-
- Hassanpour SH, Dehghani M. Review of cancer from perspective of molecular. J Cancer Res Pract. 2017;4:127–9. doi: 10.1016/j.jcrpr.2017.07.001. - DOI
Publication types
LinkOut - more resources
Full Text Sources
Research Materials